Navigation Links
Amgen Announces Positive Top-Line Results for Denosumab in Trial for Delay of Skeletal Related Events in Bone Metastases Patients Compared to Zometa(R)
Date:8/3/2009

nced cancer patients with solid tumors that have metastasized to the bone, and to patients with multiple myeloma, both groups who routinely suffer SREs," said Roger M. Perlmutter, M.D., Ph.D., executive vice president of Research and Development at Amgen. "We are very encouraged by the overall strength of the data, which we will present in a scientific forum later this year. We are also looking forward to reviewing the results of a final SRE study, in patients with advanced prostate cancer, next year."

Bone metastases, the spread of tumors to the bone, are a serious concern for many advanced cancer patients. When cancer spreads to the bone, the growing cancer cells weaken and destroy the bone around the tumor. This damage can result in a number of serious bone complications, collectively called SREs.

Full safety and efficacy data will be submitted for presentation at an upcoming medical meeting in the second half of this year.

Study Design

This was an international Phase 3, randomized, doubleblind, active controlled study comparing denosumab with Zometa in the treatment of bone metastases in patients with advanced cancer (excluding breast and prostate cancer) or multiple myeloma. Patients enrolled in this event-driven study were randomized in a one-to-one ratio to receive either 120 mg of denosumab subcutaneously every four weeks (Q4W) or Zometa administered intravenously at a dose of 4 mg single, 15 minute infusion every four weeks.

In clinical trials thus far to test new medications for bone metastases, treatment success has been measured by whether the bone complications, or SREs, caused by the tumor are reduced or delayed. The primary and secondary endpoints of the denosumab bone metastases studies use a composite endpoint of four SREs - fracture, radiation to bone, surgery to bone, and spinal cord compression - to measure the effectiveness of denosumab versus Zomet
'/>"/>

SOURCE Amgen
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8

Related medicine technology :

1. Arthritis Foundation Announces Amgen and Wyeth to Be Presenting Sponsor of the 2008 Arthritis Walk (R)
2. Medarex to Receive Milestone Payment from Amgen
3. AMT Obtains License to Amgens GDNF Gene to Develop Treatment for Parkinsons Disease with AMTs Proprietary Gene Therapy Platform
4. Amgen, Takeda and Millennium Provide Update on Phase 3 Trial of Motesanib in Patients With Non-Small Cell Lung Cancer
5. CDC Foundation Partners with Amgen, CDC to Reduce Infections Among Cancer Patients
6. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
7. EDAP Announces Launch of Clinical Study Combining HIFU and Chemotherapy for Localized Aggressive High Risk Prostate Cancer
8. Cephalon Announces Positive Results from a Pivotal Study of FENTORA in Opioid-tolerant Patients with Non-cancer Breakthrough Pain
9. ADVENTRX Announces Fast Track Designation Granted By the FDA For CoFactor For the Treatment of Metastatic Colorectal Cancer
10. DOV Pharmaceutical, Inc. Announces Successful Phase Ib Results for DOV 21,947
11. Phosphagenics Announces Positive Phase 1b Transdermal Insulin Clinical Trial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/27/2015)... -- According to a new market research ... by Deployment Mode (Web based, On-Premise, Cloud-Based), by End ... by Component - Global Trends & Forecast to 2019", ... $501.1 Million 2014, and is projected to reach $722.7 ... 2014 to 2019. Browse 60 T ...
(Date:8/27/2015)... The nation,s newest Actos trial gets underway Thursday, August 27 ... courtroom.  Attorneys representing two southern Nevada ... after using the diabetes drug Actos. "Takeda Pharmaceuticals ... that their drug Actos caused an increased risk of bladder ... hold Takeda responsible it is appropriate to seek substantial punitive ...
(Date:8/27/2015)... 2015  BioElectronics Corporation (OTC Pink: BIEL), the maker ... abstracts featuring the use of ActiPatch®, its novel musculoskeletal ... Congress of the European Pain Federation EFIC®, ... 2015. The Company will also be exhibiting at the ... Bagnato , department clinical and experimental rheumatology from the ...
Breaking Medicine Technology:Radiology Information Systems Market Worth $722.7 Million by 2019 2Radiology Information Systems Market Worth $722.7 Million by 2019 3Radiology Information Systems Market Worth $722.7 Million by 2019 42 Billion Dollar Verdict Sought In Actos Trial 2BioElectronics Selected to Present its Pain Research and Devices at the European Pain Federation Conference 2
... YORK, Oct. 18, 2011 Reportlinker.com announces ... available in its catalogue: ... to 2020 http://www.reportlinker.com/p0657234/Cervarix-Cervical-Cancer---Analysis-and-Forecasts-to-2020.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=Pathology ... Analysis and Forecasts to 2020 ...
... Reportlinker.com announces that a new market research ... Orthopedic Biomaterials, The World Market ... products, which can be organic or synthetic in ... fracture to facilitate healing or to compensate for ...
Cached Medicine Technology:Cervarix (Cervical Cancer) - Analysis and Forecasts to 2020 2Cervarix (Cervical Cancer) - Analysis and Forecasts to 2020 3Cervarix (Cervical Cancer) - Analysis and Forecasts to 2020 4Orthopedic Biomaterials, The World Market 2Orthopedic Biomaterials, The World Market 3Orthopedic Biomaterials, The World Market 4
(Date:8/27/2015)... ... August 27, 2015 , ... Healthpointe is proud to welcome ... Clinic in Los Angeles. Licensed to practice Chinese Needle Therapy since 1983, Dr. Priebe ... and diseases. Dr. Priebe also practices in Healthpointe’s La Mirada clinic and Garden Grove ...
(Date:8/27/2015)... JOHNSON CITY, Tenn. (PRWEB) , ... August 27, 2015 , ... ... Technology LLC, DBA All Clear System. The agreement will enable both Johnson City, Tenn.-based ... , All Clear System is a cloud-based safety product that caters to organizations in ...
(Date:8/27/2015)... ... 2015 , ... Florida Hospital North Pinellas, located at 1395 South Pinellas Avenue in Tarpon Springs, ... new facility will be located at US Highway 19 North and Highlands Boulevard, less than ... and work on the project is slated to begin in September 2015. , ...
(Date:8/27/2015)... ... August 27, 2015 , ... Since its launch on ... having twelve offices in three counties, LA, Orange and San Bernardino. Their ... Founded by Dr. Richy Agajanian, the Oncology Institute of Hope and Innovation ...
(Date:8/27/2015)... PITTSBURGH, PA (PRWEB) , ... August 27, 2015 , ... ... of the shower and tub," said an inventor from Camp Hill, Pa. "I developed ... He created a prototype for the BATH AND SHOWER GRIP to provide a helping ...
Breaking Medicine News(10 mins):Health News:Qualified Medical Examiner and Acupuncturist Joins Healthpointe in Los Angeles 2Health News:Qualified Medical Examiner and Acupuncturist Joins Healthpointe in Los Angeles 3Health News:Banc Intranets Forms Strategic Marketing Partnership with All Clear System 2Health News:Banc Intranets Forms Strategic Marketing Partnership with All Clear System 3Health News:Banc Intranets Forms Strategic Marketing Partnership with All Clear System 4Health News:Florida Hospital North Pinellas is Opening a New Free-Standing Emergency Room in Palm Harbor 2Health News:Florida Hospital North Pinellas is Opening a New Free-Standing Emergency Room in Palm Harbor 3Health News:California’s Largest Private Oncology Practice Serves 50,000 Patients in 8 years 2Health News:Inventor and InventHelp Client Develops Bathroom Stabilization Aid (LCC-432) 2
... You,re visiting the dentist for what you think is a ... need a root canal. Though it,s a term you,ve probably ... you may have several questions and feel apprehensive about your ... quite some time. The Pennsylvania Dental Association (PDA) wants to ...
... Healthcare is an industry faced with unprecedented uncertainty. ... overcome the noise and clearly communicate relevant and timely ... company Griffin York & Krause (GY&K) reaffirmed its commitment ... been honored with six national CardioVascular Advertising (CVA) Awards. ...
... New GREENGUARD product certification pilot significantly expands ... exposure to harmful chemicals from products used in ... The GREENGUARD Environmental Institute (GEI) announces the launch ... program incorporating existing stringent indoor air quality criteria, ...
... -- Mesa Laboratories, Inc. (Nasdaq: MLAB ) today ... quarterly dividend of $.11 per share of common stock, up ... be payable December 15, 2009, to shareholders of record on ... Labs has maintained strong cash positions and has continued to ...
... 12 Christiana Care Health System,s Helen ... in the nation to submit specimens to the Biospecimen ... Project. The project is part of a sweeping initiative ... diagnose, treat and even prevent cancer in the future. ...
... muscular dystrophy, experts say , THURSDAY, Nov. 12 (HealthDay ... into the leg muscles of monkeys helped the animals ... , The Muscular Dystrophy Association, which funded the research, ... to better treatment for people who suffer from muscle ...
Cached Medicine News:Health News:Painful Root Canals Are a Thing of the Past 2Health News:Healthcare Organizations Face Tough Marketing Challenges - GY&K Asks 'Are You Relevant?' 2Health News:Healthcare Organizations Face Tough Marketing Challenges - GY&K Asks 'Are You Relevant?' 3Health News:GREENGUARD Launches Comprehensive Health-Based Certification Pilot Program 2Health News:Christiana Care First Community Hospital to Submit Samples to Cancer Genome Atlas Project 2
... The Infinity Uric Acid single liquid ... the convenience of single liquid stability ... operator error and provide quick result ... the Infinity Uric Acid reagent provides ...
... The Infinity Glucose Oxidase single ... all the convenience of single liquid ... minimize operator error and provide quick ... of the Infinity Glucose Oxidase reagent ...
... single liquid stable reagent offers the ... liquid stability to help maximize laboratory ... quick result turnaround time. The proprietary ... provides a long shelf life that ...
... the profitability of your practice by seeing more ... VELO system you can turn a 14-18 patients ... day practice. By streamlining automated test sequences, youll ... technology is simple to learn; making it easy ...
Medicine Products: